You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company will offer 3.75 million shares of its common stock at $21 per share.
The company will use the proceeds to expand its R&D capabilities and its commercial operations.
During the second quarter of fiscal 2019, the firm took orders for genes, libraries, and oligonucleotide pools from about 780 customers.
For the quarter ended March 31, Twist reported $13.6 million in revenues, up from $6.2 million during the same period last year.
The company launched last month with initial financing of $35 million and licenses to CRISPR and synthetic biology technology from the Broad and Harvard.
The partnership follows a strategic collaboration between Twist and LakePharma, announced last week, that involves the same technology.
The company has initial financing of $35 million, and has licensed its foundational SHERLOCK and INSPECTR technologies from the Broad and Harvard, respectively.
The former cofounder of Knome believes that the future of precision medicine lies in our ability to program living things to act as medicines.
The firm recognized revenues in fiscal Q1 2019 of $11.5 million, driven by rapid growth in its NGS products as well as its synthetic biology business.
Ohio State University researchers found that a phosphorothioate-modified DNA-crRNA duplex completely blocked the function of Cas12a.
Aside from its core synthetic biology business, the company has expanded into NGS and is looking to move into drug discovery and DNA data storage.
Twist, which went public in October, reported that its revenues doubled this year due to increased sales of its synthetic DNA products and the introduction of NGS products.
CNGB was founded by the Chinese government and BGI to collect genomics technologies and resources, and promote their use by the research community.
Cowen gave the company a rating of Outperform while JP Morgan assigned its shares a Neutral rating.
The French startup plans to offer a precommercial version of its hardware platform to beta testers as early as the end of 2019.
Eurofins will distribute Synthego's sgRNA products to its customers in 44 countries.
The firm said it will use the financing to continue marketing its Engineered Cells and CRISPRevolution product lines and to expand in Europe and Asia.
The firm hasn't yet specified how many shares it is offering or at what price but noted that its stock would trade under the Nasdaq symbol TWST.
Ranomics said it has inked a distribution agreement with Axil Scientific for Ranomics' VariantFind DNA libraries in Singapore.
Arbor will provide reagents to Tataa for its courses on next-generation sequencing applications, while Tataa will distribute Arbor's products in European countries.
President Donald Trump announced the US would be leaving the World Health Organization, NBC News reports.
A study of Great Danes homes in on a genomic region linked to fearfulness.
CDC head says a new analysis indicates earlier testing wouldn't have caught viral spread, NPR reports.
In PLOS this week: gene expression and epigenetics of Indonesian populations, hookworm parasite secretome, and more.